Headache News and Research

Latest Headache News and Research

What is the viral rebound in untreated COVID-19 infections?

Researchers assessed the coronavirus disease 2019 (COVID-19) rebound in untreated COVID-19 infections.

4 Aug 2022

‘Children are not little adults’ and need special protection during heat waves

After more than a week of record-breaking temperatures across much of the country, public health experts are cautioning that children are more susceptible to heat illness than adults are — even more so when they're on the athletic field, living without air conditioning, or waiting in a parked car.

4 Aug 2022

Case series of first 3 monkeypox patients in Massachusetts treated with tecoviromat

A team of US-based scientists has described the therapeutic efficacy of a pan-Orthopoxvirus inhibitor, tecovirimat, in patients with monkeypox infection

3 Aug 2022

How can researchers profile post-COVID syndromes among distinct SARS-CoV-2 variants?

In a new study, researchers profiled post-coronavirus disease (COVID) syndrome (PCS) throughout various SARS-CoV-2 variants.

2 Aug 2022

Long-term symptoms 23 months after SARS-CoV-2 infection

Scientists analyzed COVID-19 symptoms lasting 23 months after the infection.

2 Aug 2022

Symptoms of monkeypox differ from previous outbreaks

A new study describes the clinical characteristics of monkeypox infections during the current outbreak.

1 Aug 2022

CDC study describes safety profile of second mRNA COVID booster

The CDC investigates the safety profile of a fourth dose of mRNA-based COVID-19 vaccines in people aged 50 years and older.

1 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

The effects of CBD in the treatment of COVID-19–related inflammatory symptoms

Researchers reviewed the effectiveness of cannabidiol in treating COVID-19 inflammatory-related symptoms.

28 Jul 2022

Icelandic study reveals how many children experience severe COVID symptoms

Researchers explore the incidence of SARS-CoV-2 infections in Icelandic children.

27 Jul 2022

UK study finds over 100 symptoms of long COVID in non-hospitalized adults

In a new study, researchers determined symptoms and risk factors present beyond 12 weeks in non-hospitalized adults with confirmed SARS-CoV-2 infection.

27 Jul 2022

Study confirms efficacy of molnupiravir against COVID in a real-life cohort

Researchers report the efficacy and safety of molnupiravir in treating COVID-19.

26 Jul 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 21 Jul 2022

Anti-SARS-CoV-2 nucleocapsid antibodies and pre-existing lung diseases may be independent predictors of long COVID

Researchers evaluated the incidence of long coronavirus disease (long COVID) in a demographically diverse population with different disease severities to inform clinicians and future vaccine development strategies.

21 Jul 2022

New Oxford study examines the effectiveness of pharmacological treatments for insomnia

Two drugs, eszopiclone and lemborexant - both not currently licenced for the treatment of insomnia in the UK - were shown to perform better than others, both in the acute and long-term treatment of insomnia in adults, according to a new Oxford study exploring the pharmacological management of insomnia.

19 Jul 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 19 Jul 2022

COVID-19 risks may be heightened by history of Lyme disease

Individuals with a history of Lyme disease, caused by tick bites are at a higher risk of severe COVID-19.

17 Jul 2022

CDC posts investigation notice about multistate outbreak of Listeria infections

A CDC Investigation Notice regarding a multistate outbreak of Listeria infections has been posted: Listeria Outbreak | CDC.Listeria Outbreak | CDC

10 Jul 2022

Researchers analyze acute and post-acute COVID-19 presentations in athletes

Researchers at the University of São Paulo (USP) in Brazil analyzed data from 43 scientific articles describing the effects of COVID-19 on athletes and concluded that while the disease was asymptomatic or mild in the vast majority of cases (94%), about 8% of the subjects concerned had persistent symptoms affecting their performance and potentially preventing a return to training and competing.

8 Jul 2022

Immunogenicity and safety of the protein-based heterodimer booster vaccine for COVID-19

Researchers compared the immunogenicity and safety of the protein-based heterodimer vaccine (PHH-1V) and BNT162b2 COVID-19 vaccines.

8 Jul 2022

Headache News and Research

Latest Headache News and Research

What is the viral rebound in untreated COVID-19 infections?

‘Children are not little adults’ and need special protection during heat waves

Case series of first 3 monkeypox patients in Massachusetts treated with tecoviromat

How can researchers profile post-COVID syndromes among distinct SARS-CoV-2 variants?

Long-term symptoms 23 months after SARS-CoV-2 infection

Symptoms of monkeypox differ from previous outbreaks

CDC study describes safety profile of second mRNA COVID booster

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

The effects of CBD in the treatment of COVID-19–related inflammatory symptoms

Icelandic study reveals how many children experience severe COVID symptoms

UK study finds over 100 symptoms of long COVID in non-hospitalized adults

Study confirms efficacy of molnupiravir against COVID in a real-life cohort

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

Anti-SARS-CoV-2 nucleocapsid antibodies and pre-existing lung diseases may be independent predictors of long COVID

New Oxford study examines the effectiveness of pharmacological treatments for insomnia

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

COVID-19 risks may be heightened by history of Lyme disease

CDC posts investigation notice about multistate outbreak of Listeria infections

Researchers analyze acute and post-acute COVID-19 presentations in athletes

Immunogenicity and safety of the protein-based heterodimer booster vaccine for COVID-19

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in